AI-generated from publicly available materials.Recent advancements in AI have enabled researchers to identify potential drug candidates that could combat resistant infections caused by Streptococcus pneumoniae, a significant public health threat.
Led by Pedro Ballester from Imperial College London, the research team utilized three AI algorithms to analyze nearly 7,000 approved and investigational drugs. These algorithms were trained on existing data regarding drug efficacy against resistant bacteria, resulting in the identification of 11 promising candidates. Notably, nine of these candidates demonstrated significant effectiveness in lab tests against S. pneumoniae, with one, thiostrepton, showing remarkable potency against multidrug-resistant strains.
The urgency of addressing antimicrobial resistance (AMR) is underscored by the World Health Organization's classification of multidrug-resistant S. pneumoniae as a critical global priority. Traditional treatments, primarily relying on beta-lactams and macrolides, are increasingly failing due to widespread resistance. This highlights the necessity for innovative approaches in drug development.
This study represents a pioneering application of AI for drug repurposing against S. pneumoniae, potentially reducing the time and costs associated with discovering new treatments. The researchers emphasized that the combined use of multiple AI models enhances the selection process, leading to more effective outcomes. As the fight against AMR intensifies, AI-driven drug repurposing emerges as a promising and efficient strategy to identify new therapeutic options.